Parecoxib 202409-33-4
198470-84-7
198470-85-8
Parecoxib is a water soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib and rofecoxib . As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac is used in the United States. However, unlike ketorolac, parecoxib has no effect on platelet function and therefore does not promote bleeding during or after surgery. In addition, ketorolac has a much higher gastrointestinal toxicity profile compared to most other nonsteroidal antiinflammatory drugs including ibuprofen and naprosyn. However, in the United States ketorolac is the only injectable NSAID, although it is banned in many European countries due to concerns about surgical bleeding and stomach ulcers after surgery. In 2005, the U. S. Food and Drug Administration (FDA) issued a letter of non-approval for parecoxib in the United States. No reasons were ever documented publicly for the non-approval, although one study noted increased occurrences of heart attacks following cardiac bypass surgery compared to placebo when high doses of parecoxib were used to control pain after surgery. It is also important to remember that rare but severe allergic reactions (Stevens-Johnson Syndrome, Lyell Syndrome) have been described with valdecoxib, the molecule in which parecoxib is converted . The drug is not approved for use after cardiac surgery in Europe. Ketorolac, still banned in much of Europe, is therefore the only option in the United States, and it is not clear whether parecoxib will be resubmitted to the FDA in the future. All antiiflammatory medications in the U. S. carry the same warning regarding skin reactions, and none are approved for use during CABG surgery, so the reason for the FDA denying the approval of parecoxib remains unknown.
read more [+]| Systematic (IUPAC) name: | N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl}propanamide |
|---|---|
| Parecoxib CAS number: | 202409-33-4 198470-84-7 198470-85-8 |
| ATC code: | M01AH04 |
| PubChem: | 119828 |
| DrugBank: | |
| Formula: | C19H18N2O4 |
| Molecular mass: | 370.422 g/mol |
| Parecoxib Assay/Purity: | Typically NLT 98% |
